Biomedical Research Center, The First Hospital of Kunming, People's Republic of China.
Cancer Biother Radiopharm. 2010 Aug;25(4):465-70. doi: 10.1089/cbr.2010.0762.
Cytokine-induced killer (CIK) cells have shown antitumor activity against several tumor cells both in vitro and in vivo. This study reports on the large-scale expansion of CIK cells and also present preliminary results from a pilot clinical trial. Sixteen (16) patients with renal cell carcinoma (RCC), all of whom had metastases after radical nephrectomy and adjuvant therapy using interferon-alpha (IFN-alpha) and/or interleukin-2 (IL-2), were treated with CIK cells. CIK cells were generated from peripheral blood mononuclear cells (PBMCs) and incubated in the presence of IFN-gamma followed by OKT3 and IL-2. Treatment schedule consisted of two to three cycles of CIK cell infusions at an interval of 3 weeks. A total of 46 infusions were administered to 16 metastatic RCC (mRCC) patients. The median number of transferred cells per treatment was 6.7 x 10(9) (range, 2.5-12.3). At a 60:1 effector-target cell ratio, CIK cells killed 51.4% and 32.1% of two human kidney tumor cell lines (293 and SK-RC-42), respectively. After CIK cell infusion, the percentage of CD3(+), CD8(+), CD3(+)CD56(+), and NKG2D(+) cells and the intracellular products of two type 1 cytokines (IFN-gamma and tumor necrosis factor alpha) significantly increased in the patients' PBMCs. Toxicity was minimal, and there were no immediate adverse reactions to the infusions. Three (3) patients had complete response, 1 patient had partial response, and 6 patients had stable disease. These results showed that adoptive CIK cell immunotherapy is a safe and effective treatment, which may have essential benefits for the improvement of the immunologic function in mRCC patients and play an important role in the treatment of mRCC.
细胞因子诱导的杀伤（CIK）细胞在体外和体内对多种肿瘤细胞均显示出抗肿瘤活性。本研究报告了 CIK 细胞的大规模扩增，并介绍了一项初步临床试验结果。16 例肾细胞癌（RCC）患者均接受了根治性肾切除术和辅助治疗（干扰素-α（IFN-α）和/或白细胞介素-2（IL-2）），并转移。用 CIK 细胞治疗。CIK 细胞从外周血单个核细胞（PBMC）中产生，并在 IFN-γ存在下孵育，然后用 OKT3 和 IL-2 孵育。治疗方案包括每 3 周间隔进行 2 至 3 个 CIK 细胞输注周期。共对 16 例转移性 RCC（mRCC）患者进行了 46 次输注。每次治疗转移的细胞中位数为 6.7 x 10（9）（范围，2.5-12.3）。在 60：1 的效应器-靶细胞比下，CIK 细胞分别杀死了两个人肾肿瘤细胞系（293 和 SK-RC-42）的 51.4％和 32.1％。CIK 细胞输注后，患者 PBMC 中的 CD3（+），CD8（+），CD3（+）CD56（+）和 NKG2D（+）细胞的百分比以及两种 1 型细胞因子（IFN-γ和肿瘤坏死因子α）的细胞内产物均显著增加。毒性最小，输注后无立即不良反应。3 例患者完全缓解，1 例患者部分缓解，6 例患者病情稳定。这些结果表明，过继性 CIK 细胞免疫疗法是一种安全有效的治疗方法，可能对改善 mRCC 患者的免疫功能具有重要意义，并在治疗 mRCC 中发挥重要作用。
